Organisation paid for research Program year 2024 Source: CMS Open Payments

Cis Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$333,973

24 payments

Through program year 2024, Cis Clinical Research is reported as receiving $333,973 in research payments, across 24 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $124,632 7
2023 Research $133,405 10
2022 Research $19,254 2
2021 Research $30,761 3
2020 Research $20,444 1
2019 Research $5,477 1

Breakdown

Who paid Research payments · program years 2019–2024
  1. Novartis Pharmaceuticals Corporation $317,248 22 payments
  2. Terumo Medical Corporation $16,725 2 payments
Studies the money was for Research payments · program years 2019–2024
  1. Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $158,185 11 payments
  2. A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardiovascular disease $52,635 1 payment
  3. Multi-center cross-sectional epidemiological study to characterize the prevalence and distribution of lipoprotein(a) levels among patients with established cardiovascular disease $40,705 3 payments
  4. A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein (A) Lowering With Tqj230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease $30,786 4 payments
  5. A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) $29,460 2 payments
  6. Osprey Iliac: Occlusive/Stenotic Peripheral Artery Revascularization Study for Common And/Or External Iliac Artery Using the Misago RX Self-Expanding Peripheral Stent $16,725 2 payments
  7. A Randomized Double Blind Placebo Controlled Event Driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post Myocardial Infarction Patients With Elevated Hscrp $5,477 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record